SG11201501505WA - Methods for producing cells having a phenotype of a primary human hepatocytes and compositions - Google Patents

Methods for producing cells having a phenotype of a primary human hepatocytes and compositions

Info

Publication number
SG11201501505WA
SG11201501505WA SG11201501505WA SG11201501505WA SG11201501505WA SG 11201501505W A SG11201501505W A SG 11201501505WA SG 11201501505W A SG11201501505W A SG 11201501505WA SG 11201501505W A SG11201501505W A SG 11201501505WA SG 11201501505W A SG11201501505W A SG 11201501505WA
Authority
SG
Singapore
Prior art keywords
phenotype
compositions
methods
producing cells
primary human
Prior art date
Application number
SG11201501505WA
Other languages
English (en)
Inventor
Lorne D Tyrrell
Hendrikje Geesje Steenbergen
Michael A Joyce
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of SG11201501505WA publication Critical patent/SG11201501505WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10151—Methods of production or purification of viral material
    • C12N2730/10152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • C12N2770/24252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201501505WA 2012-08-31 2013-08-30 Methods for producing cells having a phenotype of a primary human hepatocytes and compositions SG11201501505WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261696059P 2012-08-31 2012-08-31
US201361761588P 2013-02-06 2013-02-06
PCT/IB2013/002501 WO2014033546A2 (en) 2012-08-31 2013-08-30 Methods for producing cells having a phenotype of a primary human hepatocytes and compositions

Publications (1)

Publication Number Publication Date
SG11201501505WA true SG11201501505WA (en) 2015-03-30

Family

ID=50184510

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501505WA SG11201501505WA (en) 2012-08-31 2013-08-30 Methods for producing cells having a phenotype of a primary human hepatocytes and compositions

Country Status (13)

Country Link
US (1) US9969979B2 (ja)
EP (1) EP2890779B1 (ja)
JP (1) JP6427100B2 (ja)
KR (1) KR102089477B1 (ja)
CN (1) CN104755606B (ja)
AU (1) AU2013308113B2 (ja)
CA (1) CA2883146C (ja)
DK (1) DK2890779T3 (ja)
ES (1) ES2651414T3 (ja)
HK (1) HK1207884A1 (ja)
IL (1) IL237435B (ja)
SG (1) SG11201501505WA (ja)
WO (1) WO2014033546A2 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106471119B (zh) 2014-04-18 2020-11-10 思齐乐 用于增加产量的组合物和方法
US10988737B2 (en) 2015-04-28 2021-04-27 Universite De Strasbourg Clinical gene signature-based human cell culture model and uses thereof
JP6869543B2 (ja) * 2015-12-22 2021-05-12 公立大学法人横浜市立大学 ウイルス感染モデル、その作製方法及びその利用
JP7039045B2 (ja) * 2019-08-26 2022-03-22 株式会社フェニックスバイオ ヒト脂肪肝モデル細胞

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
ES2378409T3 (es) 1994-11-10 2012-04-12 Baxter Healthcare S.A. Método para producir sustancias biológicas en cultivo sin proteínas
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
WO1996024662A1 (en) 1995-02-10 1996-08-15 Consiglio Nazionale Delle Ricerche Process to 'in vitro' propagate the hepatitis c virus (hcv) in non lymphoblastoid animal cell cultures and products thereof
US5798250A (en) 1996-04-15 1998-08-25 Icn Pharmaceuticals, Inc. Facilitating hepatitus virus infection in cell culture using a membrane stressor
US6458585B1 (en) 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
WO1998006823A2 (en) 1996-08-14 1998-02-19 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
CA2269097C (en) 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
US6627426B2 (en) 1997-02-14 2003-09-30 Invitrogen Corporation Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby
EP0972828A1 (en) * 1998-06-24 2000-01-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Process for the in vitro replication of HCV
US20040229336A1 (en) 1999-07-30 2004-11-18 Bio Merieux Method for in vitro culture of viruses of the togaviridae and flaviviridae families and uses
JP4499990B2 (ja) * 2001-03-27 2010-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Ｈｃｖ感染に有用な組成物および方法
ATE458039T1 (de) 2001-07-06 2010-03-15 Inst Nat Sante Rech Med Menschliche hepatomazellinien, deren gewinung und deren verwendungen
WO2003011209A2 (en) 2001-07-31 2003-02-13 Yeda Research And Development Co. Ltd. Methods of sensitizing hepatocyte cell cultures to hepatitis infection, beads coated with hbv or hcv polypeptides and methods of using such beads to model viral infection or deliver substances into hepatocytes
AU2003217700A1 (en) 2002-02-26 2003-09-09 Stelsys Llc Hepatocyte bioreactor system for long term culture of functional hepatocyte spheroids
CN1711352A (zh) 2002-11-13 2005-12-21 华盛顿大学 丙型肝炎病毒复制的高允许性细胞系
DK1694694T3 (da) 2003-12-01 2013-05-06 Univ Texas Replikationskompetent hepatitis C-virus samt anvendelsesfremgangsmåder
US20080286752A1 (en) 2005-04-08 2008-11-20 The Trustees Of Columbia University In The City Of New York Methods for the production of HCV, assaying HCV entry, and screening drugs and cellular receptors for HCV
WO2007046962A2 (en) 2005-09-02 2007-04-26 The University Of Maryland, Baltimore Cell lines harboring hepatitis virus and methods for using thereof
US7759087B1 (en) 2005-09-28 2010-07-20 The Florida State University Research Foundation, Inc. Method of indefinite culture of hepatitis C virus
WO2009025759A1 (en) 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
CN102149817A (zh) * 2008-09-12 2011-08-10 弗·哈夫曼-拉罗切有限公司 在细胞培养物中产生感染性丙型肝炎病毒颗粒
US8921108B2 (en) 2009-04-21 2014-12-30 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Differentiated human liver cell cultures and their use in bioartificial liver systems
ES2360782B1 (es) 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.

Also Published As

Publication number Publication date
CN104755606A (zh) 2015-07-01
CN104755606B (zh) 2019-04-12
EP2890779A2 (en) 2015-07-08
CA2883146C (en) 2022-05-17
EP2890779A4 (en) 2016-08-03
AU2013308113A1 (en) 2015-03-19
KR20150048868A (ko) 2015-05-07
US9969979B2 (en) 2018-05-15
JP6427100B2 (ja) 2018-11-21
US20150184124A1 (en) 2015-07-02
DK2890779T3 (da) 2017-11-27
AU2013308113B2 (en) 2019-01-17
IL237435A0 (en) 2015-04-30
HK1207884A1 (en) 2016-02-12
KR102089477B1 (ko) 2020-03-17
IL237435B (en) 2019-11-28
CA2883146A1 (en) 2014-03-06
ES2651414T3 (es) 2018-01-26
WO2014033546A3 (en) 2014-04-17
JP2015528291A (ja) 2015-09-28
EP2890779B1 (en) 2017-10-04
WO2014033546A2 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
HK1212384A1 (en) Methods and compositions for producing induced hepatocytes
GB2516540B (en) Protective case and methods of making
ZA201508059B (en) Compositions and methods of use of phorbol esters
HK1215785A1 (zh) 控制釋放組合物及使用方法
EP2836224A4 (en) COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2734049A4 (en) PROBIOTIC COMPOSITIONS AND METHOD
IL230237B (en) Fat Cell Compounds and Methods
GB201200458D0 (en) Methods of preparing cells and compositions
EP2704688A4 (en) COZY COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE
HK1198122A1 (en) Eosinophil peroxidase compositions and methods of their use
EP2611791A4 (en) OLIGOOXOPIPERAZINES AND METHODS FOR THEIR PREPARATION AND USE
HK1207884A1 (en) Methods for producing cells having a phenotype of a primary human hepatocytes and compositions
EP2670245A4 (en) ALPHA-CÉTOHÉTÉROCYCLES AND METHODS OF MAKING AND USING THEM
IL231490A0 (en) Preparations and methods for the production and use of human cholinesterases
IL239623A0 (en) Methods and preparations for administering oxybutynin